Clinical trial
Effect of an Internet Based Compliance Enhancement Tool in Subjects With…
NCT00240357 · AstraZeneca, Industry · Withdrawn
Key facts
| NCT number | NCT00240357 |
|---|---|
| Title | Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia |
| Official title | Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement of LDL Goals. - Denmark |
| Lead sponsor | AstraZeneca, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia |
| Intervention type | Procedure |
| Interventions | Lifestyle Regulation |
| Enrollment | 1,175 |
| Start date | Feb 1, 2003 |
| First posted | Oct 18, 2005 |
| Last update posted | Mar 26, 2009 |
| Countries | Denmark |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: